Matches in DBpedia 2016-04 for { <http://wikidata.dbpedia.org/resource/Q17001240> ?p ?o }
Showing triples 1 to 30 of
30
with 100 triples per page.
- Q17001240 subject Q10078446.
- Q17001240 subject Q7334142.
- Q17001240 subject Q8419336.
- Q17001240 subject Q8872471.
- Q17001240 subject Q9019802.
- Q17001240 subject Q9546190.
- Q17001240 abstract "Fostemsavir (BMS-663068) is an experimental HIV entry inhibitor and a prodrug of temsavir (BMS-626529). It is under development by Bristol-Myers Squibb for use in the treatment of HIV infection. By blocking the gp120 receptor of the virus, it prevents initial viral attachment to the host CD4+ T cell and entry into the host immune cell; its method of action is a first for HIV drugs. Because it targets a different step of the viral lifecycle, it offers promise for individuals with virus that has become highly resistant to other HIV drugs. Since gp120 is a highly conserved area of the virus, the drug is unlikely to promote resistance to itself via generation of CD4-independent virus.".
- Q17001240 iupacName "{3-[(4-Benzoyl-1-piperazinyl)(oxo)acetyl]-4-methoxy-7-(3-methyl-1H-1,2,4-triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-1-yl}methyl dihydrogen phosphate".
- Q17001240 thumbnail Fostemsavir_structure.svg?width=300.
- Q17001240 wikiPageWikiLink Q10078446.
- Q17001240 wikiPageWikiLink Q1345259.
- Q17001240 wikiPageWikiLink Q15787.
- Q17001240 wikiPageWikiLink Q182506.
- Q17001240 wikiPageWikiLink Q2198549.
- Q17001240 wikiPageWikiLink Q266423.
- Q17001240 wikiPageWikiLink Q603741.
- Q17001240 wikiPageWikiLink Q7334142.
- Q17001240 wikiPageWikiLink Q8419336.
- Q17001240 wikiPageWikiLink Q8872471.
- Q17001240 wikiPageWikiLink Q9019802.
- Q17001240 wikiPageWikiLink Q9546190.
- Q17001240 iupacname "{3-[acetyl]-4-methoxy-7--1H-pyrrolo[2,3-c]pyridin-1-yl}methyl dihydrogen phosphate".
- Q17001240 type ChemicalCompound.
- Q17001240 type ChemicalSubstance.
- Q17001240 type ChemicalObject.
- Q17001240 type Thing.
- Q17001240 type Q11173.
- Q17001240 comment "Fostemsavir (BMS-663068) is an experimental HIV entry inhibitor and a prodrug of temsavir (BMS-626529). It is under development by Bristol-Myers Squibb for use in the treatment of HIV infection. By blocking the gp120 receptor of the virus, it prevents initial viral attachment to the host CD4+ T cell and entry into the host immune cell; its method of action is a first for HIV drugs.".
- Q17001240 label "Fostemsavir".
- Q17001240 depiction Fostemsavir_structure.svg.